MedTrace Logo

Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer

NCT01956149 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2018-04-18

No results posted yet for this study

Summary

Single-arm study to determine disease control rate in second- (or later) line treatment with cabazitaxel after the failure of palliative primary treatment.

Conditions

Interventions

DRUG

Cabazitaxel

20 mg/m2 over 1 hour i.v., repeated on day 22 for maximum 6 cycles.

Sponsors & Collaborators

  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

    lead OTHER

Principal Investigators

  • Harald Schmalenberg, MD · Krankenhaus Dresden Friedrichstadt

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2017-12-31
Completion
2018-04-04

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01956149 on ClinicalTrials.gov